1. Metastatic Melanoma Treatment and Prophylaxis with S100A9-Targeting Cowpea Mosaic Virus Nanoparticles.
- Author
-
Chung YH and Steinmetz NF
- Subjects
- Animals, Mice, Humans, Melanoma therapy, Melanoma immunology, Melanoma pathology, Cell Line, Tumor, Immunotherapy methods, Neoplasm Metastasis prevention & control, Melanoma, Experimental immunology, Melanoma, Experimental therapy, Melanoma, Experimental pathology, Comovirus chemistry, Nanoparticles chemistry, Calgranulin B metabolism
- Abstract
Metastatic cancer continues to be the main cause of cancer-related death, and new therapies must be continuously researched to eradicate these cancers. Immunotherapy aims to stimulate the patient's own immune system to recognize and eliminate tumors and metastatic sites. A particular powerful approach is the use of immunostimulatory agents to reprogram the tumor microenvironment from "cold" to "hot" to prime systemic antitumor immunity. Plant viruses have been investigated for this purpose because their repetitive coat protein structures with encapsidated nucleic acids render them potent immunostimulatory agents. In particular, the cowpea mosaic virus (CPMV) has been found to be a potent anticancer agent when injected intratumorally. However, metastatic cancers cannot be injected in situ, and therefore a systemically administered CPMV prevention and treatment option that is targeted to S100A9 was developed. S100A9 is an immunostimulatory protein that regulates metastatic cancer seeding and growth, thereby making it an attractive target for both prevention and treatment. Protocols for the production and characterization of S100A9-targeted CPMV nanoparticles are described and in vivo experiments that can be carried out to assess the efficacy of the S100A9-targeted CPMV nanoparticles in the prevention and treatment of metastatic melanoma to the lung are detailed. Finally, instructions for flow cytometry analysis of the innate immune cell composition within the lungs following S100A9-targeted CPMV administration are provided., (© 2025. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2025
- Full Text
- View/download PDF